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End-binding protein (EB1) is a microtubule protein that binds to the tumor suppressor adenoma-
tous polyposis coli (APC). While EB1 is implicated as a potential oncogene, its role in cancer progres-
sion is unknown. Therefore, we analyzed EB1/APC expression at the earliest stages of colorectal
carcinogenesis and in the uninvolved mucosa (‘‘ﬁeld effect’’) of human and animal tissue. We also
performed siRNA-knockdown in colon cancer cell lines. EB1 is up-regulated in early and ﬁeld carci-
nogenesis in the colon, and the cellular/nano-architectural effect of EB1 knockdown depended on
the genetic context. Thus, dysregulation of EB1 is an important early event in colon carcinogenesis.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The cytoskeleton plays a major role in cancer development and
progression. Alterations in cytoskeletal regulatory pathways affect
both the structure and function of the cytoskeleton, ultimately
leading to tissue disruption, invasion, and genomic instability [1–
3]. Dysregulation of cytoskeletal proteins are a critical early event
of colon cancer initiation and progression [1,4,5]. Numerous stud-
ies have demonstrated that the adenomatous polyposis coli (APC)
tumor suppressor gene is lost in more than 80% of all colorectal
cancers and occurs during the earliest stages of carcinogenesis
[6,7]. APC is a multi-functional protein responsible in regulating
cellular b-catenin levels, cell differentiation, and maintaining
microtubule stability, though the precise role of APC regulating
the cytoskeleton during colon cancer remains unknown [8–10].
Microtubule end-binding protein 1 (EB1) was originally discovered
as a binding partner of APC [11]. EB1 is encoded by the MAPRE1
gene and a member of the RP/EB family member involved the
regulation of microtubule polymerization, cell polarity and
chromosomal stability [12,13]. Together with APC, EB1 regulateschromosomal stability during mitosis [14]. Despite being an
important binding partner of APC, the role of EB1 in colon
carcinogenesis has not been well established. However, recent re-
ports suggest that EB1 itself may play an important role in
tumorigenesis.
Studies have demonstrated EB1 overexpression in hepatocellu-
lar carcinoma, gastric carcinoma, esophageal squamous cell carci-
noma (ESCC) and breast cancer [15–18]. These studies indicate
that EB1 promotes cellular proliferation and tumor growth,
through the activation of b-catenin signaling [18,19]. However,
MAPRE1 does not appear to be involved in somatic CRC and the
role of EB1 regulation during CRC initiation and progression has
not been extensively studied [20].
In the present study, we analyzed the expression of EB1 during
early colorectal carcinogenesis and ﬁeld carcinogenesis using the
azoxymethane (AOM) rat model, polyposis in rat colon (Pirc) mod-
el and human samples. The AOM rat model is a chemically induced
model of CRC, while the Pirc rat model is a genetic model of CRC
through mutation of APC. We found that EB1 is markedly up-regu-
lated at a pre-neoplastic time point in the AOM rat model. Simi-
larly, we found that EB1 is also up-regulated in the histologically
normal tissue in the Pirc rat model and AOM rat model. Given
the potential clinical impact of EB1 dysregulation, we used low-
coherence enhanced backscattering (LEBS) technique to study
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knocked down EB1 in colon cancer cell lines with different APC sta-
tus, HT-29 (APCmut/mut) and HCT-116 (APCwt/wt). Knockdown of EB1
resulted in different phenotypes based on the genetic context of
the cell line, as seen by apoptosis, proliferation markers and LEBS
spectral analysis. We report that EB1 is a proto-oncogene and pro-
pose that EB1 dysregulation is one of the earliest events in colon
carcinogenesis.
2. Materials and methods
2.1. Cell lines and tissues
HT-29 and HCT-116 cells were grown in McCoy’s 5A medium
(ATCC, Manassas, VA) and supplemented with 10% fetal bovine ser-
um + 50 mg/mL penicillin/streptomycin under 5% CO2 environ-
ment at 37 C. All animal procedures were reviewed and
approved by the Institutional Animal Care and Use Committee (IA-
CUC) for NorthShore University HealthSystem. Fisher 344 rats
(Harlan, Madison, WI) on a standard AIN76a diet were treated with
either 2 weekly injections (i.p.) of 15 mg/kg Azoxymethane (AOM)
or saline (Midwest Research Institute, Kansas City, MO). Rats were
euthanized after 10 (pre-malignant time point) or 37 weeks (tumor
bearing time point) post AOM injection. Genetic mutation of the
Pirc rat model has been described [21]. For this study, male Pirc
rats were obtained at 12 weeks of age (Taconic, Hudson, NY) and
fed a standard AIN76a diet. Rats were euthanized at 24 weeks of
age and adenocarcinomas in the colon were noted.
2.2. Immunohistochemistry
Human tissue microarrays (Collaborative Human Tissue Net-
work, CHTN) were deparafﬁnized and then rehydrated with xylene
and graded alcohol washes. Heat-induced epitope retrieval was
performed using a pressure cooker. After quenching of endogenous
peroxidase activity in 3% hydrogen peroxide, the slides were
blocked with 5% horse serum. The slides were incubated overnight
in EB1 (BD Biosciences, San Jose, CA) or APC (C-terminus) antibody
(Santa Cruz Biotechnology, Santa Cruz, CA), followed by incubation
with the appropriate biotinylated secondary antibody. Finally, the
sections were developed using an avidin–biotin complex (ABC) kit
(Vector Laboratories, Burlingame, CA). An observer blinded to the
patient group scored the slides.
2.3. Transfection and cell viability assay
EB1 small-interfering RNAs (siRNAs) were transfected with
lipofectamine 2000 reagent (Invitrogen Life Technologies, Grand
Island, NY) in HT-29 and HCT-116 cells, following manufacturer’s
instructions. Cells were then incubated in normal conditions for
72 h in 96-well plates. At the end of the incubation, WST-1 reagent
(Roche Diagnostics, Indianapolis, IN) was added. Following 30 min
incubation with WST-1, the plate absorbance was read at 440 nm
and 600 nm using the Spectramax Plus Spectrophotometer plate
reader (Molecular Devices, Sunnyvale, CA).
2.4. Quantitative real time polymerase chain reaction (qRT-PCR)
RNA was isolated from samples using TRI Reagent (Molecular
Research Center, Inc., Cincinnati, OH). Complementary DNA (cDNA)
synthesis was performed using 5 lg of RNA and Superscript RT
(Invitrogen Life Technologies, Grand Island, NY), following stan-
dard protocol. Ampliﬁcation of cyclinD1 and c-myc was performed
using nested PCR protocols [22]. MAPRE1 PCR reactions were
carried out using 80 nM of the TaqMan probe and PCR Mastermix(Applied Biosystems, Carlsbad, CA) in a Cepheid Smart Cycle
(Cepheid, Sunnyvale, CA). All samples were normalized to b-actin
and average fold differences were calculated using the comparative
Ct method [23]. Threshold of fold change signiﬁcance was set as
>1.5 (up-regulation) and <0.67 (down-regulation).
2.5. Western blotting
Proteins were resolved on SDS/PAGE gels and transferred onto
polyvinylidene diﬂuoride (PVDF) membranes (Millipore, Billerica,
MA). Membranes were blocked in a 5% non-fat dry milk in Tris-buf-
fered saline containing 0.1% Tween 20. Membranes were incubated
overnight in EB1 antibody (BD Biosciences, San Jose, CA) at 4 C and
then with the appropriate horseradish peroxidase-conjugated sec-
ondary antibody. Proteins were developed with enhanced chemilu-
minescence reagent (Santa Cruz Biotechnology, Santa Cruz, CA).
The protein intensities were visualized using the UVP LabWorks
system and software (UVP, Upland, CA).
2.6. Flow cytometry
HT-29 and HCT-116 transfected with EB1 siRNA and control
cells were ﬁxed 72 h post-transfection. For apoptosis analysis, cells
were ﬁxed with ice-cold methanol and subsequently stained with
M30 CytoDEATH-FITC, according to manufacturer’s protocol
(Roche Applied Science, Indianapolis, IN). The CellQuest 3.1 soft-
ware programwas used to generate frequency histograms and data
analysis.
2.7. LEBS instrumentation
The LEBS setup has been described in detail previously [24].
Brieﬂy, LEBS enables simultaneous measurements of a scattering
spectrum (400–700 nm) for a range of backscattering angles
(15 to 15). The angular measurements were used to identify
an enhanced backscattering peak and then the spectral properties
of the enhanced backscattering were measured. The LEBS peak
(Fig. 4A) can be characterized by three parameters: width (W, aver-
age full width at half maximum), enhancement factor (E, average
height), and spectral slope (S, linear coefﬁcient from a linear
regression). Cells were grown in 6-well plates, trypsinized, and
pelleted. Nine separate measurements were obtained for each cell
pellet. The variability between cell pellets was statistically non-
signiﬁcant (P > 0.42). The LEBS markers from each experimental
repeat were averaged.
2.8. LEBS statistical analysis
Previously, we have established a prediction rule based on LEBS
spectral analysis for detection of ﬁeld carcinogenesis in rectum and
duodenum to predict risk of colon and pancreatic lesions else-
where in the organ [24,25]. We used this binary logistic regression
LEBS marker to evaluate and predict similar effect of EB1 knock-
down in cells [26]. In short, the three LEBS parameters (E(P1),
W(P2), SS(P3)) were used as predictors by performing univariates
analysis (ANOVA). To statistically construct a multivariable logistic
model, all parameters with P < 0.25 from univariate logistic regres-
sion were entered into the model and removed reversely, with the
ﬁnal model retaining parameters with P < 0.05. The correlation
coefﬁcient was calculated for the selected parameters and veriﬁed
to be non-signiﬁcant. The ﬁnal combined LEBS marker was built as
linear combination of LEBS parameters as: LEBS Marker = a0 + a1*-
P1 + a2*P2 + a3*P3. The prediction rule development was carried out
on HT-29 cells and then applied to HCT-116 cells. All P values were
calculated using Student’s t-tests.
Fig. 1. Immunohistochemical staining of EB1 and APC during human colon cancer progression. (A) Expression of EB1 and APC (c-terminus) in human normal, adenoma, and
adenocarcinoma colonic tissues. (B) Quantiﬁcation of the expression of EB1 and APC in adenoma and adenocarcinoma samples compared to normal tissue,⁄P < 0.01.
(C) Correlation between EB1 and APC in adenoma tissue. High expression indicates an intensity score of 3 or higher.
Fig. 2. MAPRE1 is increased in early carcinogenesis and the uninvolved mucosa. (A) EB1 expression at a pre-neoplastic time point of the AOM rat model (10 weeks), and in the
uninvolved mucosa (‘‘ﬁeld’’) of the AOM rat model (tumor-bearing time point, 37 weeks) and the Pirc rat model using qRT-PCR. Standard error bars shown, ⁄P < 0.05. (B)
Protein expression of EB1 and APC (c-terminus) in the early colon carcinogenesis model. (C) Protein expression of EB1 and APC (c-terminus) in the uninvolved mucosa in both
a chemically induced rat model (AOM) and genetic Pirc rat model of colon carcinogenesis. (D) Quantiﬁcation of protein expression conﬁrm reduced APC levels with increased
EB1 levels, ⁄P < 0.1.
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Fig. 3. EB1 knockdown in colon cancer cell lines induced changes in proliferation and apoptosis. (A) Western blotting indicates 60–80% loss of EB1 in HT-29 and HCT-116 cell
lines following siRNA-mediated knockdown. (B) WST-1 assay showed that EB1 knockdown decreased HT-29 cell proliferation (P < 0.05) but did not signiﬁcantly affect HCT-
116 cells. (C) Knockdown of EB1 decreased cyclinD1 and c-myc expression in APCmut/mut HT-29 cells, but did not affect expression of these Wnt pathway members in APCwt/wt
HCT-116 cells, using PCR. Expression was normalized to b-actin, ⁄P < 0.05. (D) Control and EB1 knockdown cells were then subjected to ﬂow cytometric analysis to measure
M30 (apoptosis marker) levels. EB1 knockdown induced apoptosis in APCwt/wt HCT-116 cells (120% of control; P = 0.06), it did not affect apoptosis in APCmut/mut HT-29 cells.
Error bars represent standard error.
832 Y. Stypula-Cyrus et al. / FEBS Letters 588 (2014) 829–8353. Results
3.1. EB1 is overexpressed in human colorectal adenoma and
adenocarcinoma concomitant with APC reduction
A recent proteomic study showed that EB1 expression is in-
creased in the tumor of CRC patients [27]. To determine whether
EB1 is implicated in the development and progression of CRC, we
ﬁrst examined its expression in human colon tissue specimens by
immunohistochemistry. Expression of EB1 was found at a low level
in all normal colon tissues samples examined (Fig. 1A). Approxi-
mately 50% of patients harboring an adenoma had high levels of
EB1 expression. Compared to the normal colon, EB1 expression
was signiﬁcantly increased in adenoma cases (P < 0.01; Fig. 1B).
Furthermore, 60% of adenocarcinoma patients also showed ele-
vated levels of EB1 expression compared to the normal colon
(P < 0.01; Fig. 1B). APC levels were signiﬁcantly reduced in the ade-
noma and adenocarcinoma cases compared to the normal colon, as
expected (Fig. 1A). We next considered the adenoma tissue samples
to assess a correlation between APC and EB1 expression. However,
there was no signiﬁcant correlation, possibly due to the relatively
limited sample size (n = 30 adenoma patients) (Fig. 1C).
3.2. EB1 is overexpressed in early and ﬁeld colorectal carcinogenesis
While it has been shown that EB1 is overexpressed in tumor
samples, the expression of EB1 in pre-malignant tissue has notyet been determined. Therefore, to study the involvement of
EB1 in early colorectal carcinogenesis and ﬁeld carcinogenesis,
we analyzed MAPRE1 expression in different time points of the
azoxymethane (AOM)-injected rat model using qRT-PCR methods.
This model recapitulates many of the genetic and epigenetic fea-
tures of human ﬁeld carcinogenesis [28]. At a premalignant time
point (10 weeks post-AOM injection), we found that MAPRE1
expression was 1.5-fold higher in the AOM-injected animals com-
pared to their age-matched control counterparts (P < 0.05;
Fig. 2A). Furthermore, at a cancerous time point of the AOM rat
model (37 weeks post-AOM injection) MAPRE1 was more than
1.5-fold higher in the AOM uninvolved mucosa compared to con-
trol animals (P < 0.01; Fig. 2A). While these results demonstrate
signiﬁcant up-regulation of EB1 during early and ﬁeld colon carci-
nogenesis, the AOM rat model cancer progression does not occur
through APC mutation. We therefore analyzed MAPRE1 expres-
sion in the uninvolved mucosa of the Pirc (polyposis in rat colon)
rat model for familial adenomatous polyposis (FAP), which devel-
ops colonic tumors in an APC mutant environment [21]. EB1
expression was 2-fold higher in Pirc rats containing a germline
APC mutation compared to APC wildtype animals (P < 0.05;
Fig. 2A), demonstrating EB1 up-regulation as a general event in
early and ﬁeld colorectal carcinogenesis. Next, immunohisto-
chemical staining was performed for EB1 and APC. In early colon
carcinogenesis (10 week AOM rat), EB1 was signiﬁcantly up-regu-
lated whereas APC was down-regulated (Fig. 2B). Similarly, EB1
was over-expressed while APC was down-regulated in both the
Fig. 4. EB1 knockdown caused alterations in sub-diffractional cell structure. We used the novel low-coherence enhanced backscattering (LEBS) technique to measure
nanoscale changes in cellular structure. (A) The LEBS peak results from the backscattered intensity of a sample, as described in Material and Methods. (B) Effect size percent
between control and EB1 knockdown cells was calculated and averaged between experiments for each cell line. The effect size percent is greatly affected by EB1 knockdown
in the HT-29 cells (P < 0.001), but caused a more modest difference in HCT-116 cells (P = 0.14). Error bars represent standard error.
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(Pirc) for ﬁeld carcinogenesis (Fig. 2C). The relative protein
expression quantiﬁcation conﬁrmed increased EB1 and reduced
APC (P < 0.1; Fig. 2D). The animal results support the human data
in which up-regulation of EB1 occurs in early colon carcinogene-
sis. Therefore, this is the ﬁrst report demonstrating EB1 up-
regulation in the pre-neoplastic tissue and ﬁeld carcinogenesis.
3.3. Loss of EB1 affects proliferation and apoptosis dependent on the
cell line
To test the hypothesis that EB1 is a proto-oncogene in colon
cancer, we studied the role of EB1 in proliferation and apoptosis
by siRNA-mediated knockdown in an APC mutant (HT-29) and
APC wildtype (HCT-116) colon cancer cell lines. Using the WST-1
assay, we found that EB1 knockdown decreased the rate of
proliferation in HT-29 cells, but not in HCT-116 cells (Fig. 3B). Pre-
vious reports have suggested that EB1 regulates proliferation
through WNT/b-catenin pathways, showing alterations in cyclin
D1 and c-myc [19]. We found that EB1 knockdown signiﬁcantly
decreased both cyclin D1 and c-myc expression in HT-29 cells,
but not in HCT-116 cells (Fig. 3C). Taken together, these results
indicate that EB1 knockdown signiﬁcantly reduced cell prolifera-
tion in APC mutant cells but has little effect in an APC wildtype
environment.
Considering the dissimilar proliferation results between HT-29
and HCT-116 cells, we next examined apoptosis. Control and EB1
knockdown cells were subjected to M30 CYTOdeath-FITC staining
and ﬂow cytometry analysis. The M30 antibody recognizes a cas-
pase-cleaved epitope of the cytokeratin-18 protein to target cells
undergoing apoptosis [29]. In HT-29 cells, there was no differ-
ence in M30 intensity in the EB1 knockdown compared to con-
trol cells. In contrast, we found a 20% increase in M30
intensity in the HCT-116 cells following EB1 knockdown com-
pared to HCT-116 control cells (P = 0.06, Fig. 3D). In view of
the important interaction of APC and EB1, the anti-proliferative
effect of EB1 knockdown may depend on the cell line, and partic-
ularly the APC status.3.4. Low coherence enhanced backscattering (LEBS) measurements
of cytoskeletal alterations
The LEBS marker is sensitive to micro-architectural alterations
in both the AOM rat model and in human cancers [24,30]. Recently,
our group has shown that cytoskeletal organization in epithelial
cells is an important factor in determining differences in LEBS
markers between control and pre-neoplastic mucosa [31]. In HT-
29 cells, the LEBS marker was signiﬁcantly decreased with EB1
knockdown compared to control cells (P < 0.01; Fig. 2). However,
in HCT-116 cells, the same LEBS marker was not as signiﬁcantly af-
fected by knockdown of the EB1 (P = 0.14; Fig. 2). Similarly, the ef-
fect size difference between HT-29 and knockdown cell line was
56% whereas in the HCT-116 cell lines, it was only 21%. These re-
sults also demonstrate a different response to EB1 knockdown
among cell lines, indicating distinct ultra-structural consequences
between the cell lines.
4. Discussion
Early detection and intervention of cancer have been shown to
greatly increase patient survival and provides a promising ap-
proach to combating cancer. Our group has developed novel optical
techniques to target the earliest stages of carcinogenesis, such as
LEBS. For the current study, we used the same LEBS prediction rule
that previously has shown that ultra-structural alterations occur in
very early stages in diffuse ﬁeld of organs (colon and pancreas) at
length scales as small as 40 nm, which are irresolvable by conven-
tional light microscopy [24,25]. Following this well-established
capability of LEBS to detect ultra-structural manifestations and
nanoscale, we used this technique to probe and understand cellular
and proteomic processes resulting from these ultra-structural
changes. Proper regulation of the cytoskeleton is a dynamic and
crucial process for normal cell function, including proliferation,
apoptosis and differentiation [10]. The microtubule-associate pro-
tein EB1 is a binding partner to APC, which is a key tumor suppres-
sor frequently mutated in both sporadic and familial colorectal
cancer (CRC). While it has been shown that EB1 is a potential
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gression has not yet described. In this study, we demonstrate that
EB1 is up-regulated in human CRC progression, consistent with
APC down-regulation. Furthermore, we show that EB1 is signiﬁ-
cantly up-regulated at the message and protein level in both genet-
ic and chemically induced models of CRC, also consistent with a
decrease in APC. Therefore, we hypothesized that knockdown of
EB1 in colon cancer cell lines would reduce cell tumorigenicity.
We found that knockdown of EB1 induced apoptosis or decreased
proliferation, depending on the genetic context of the cell line,
which was also reﬂected by differential spectral analysis using
LEBS.
The contrast in apoptotic induction between HT-29 and HCT-
116 cells following EB1 knockdown may relate to the different
p53 gene status, which is a critical regulator of apoptosis [32,33].
While there are a number of genetic differences between the cell
lines, clearly the context plays an important role in the effect of
EB1 knockdown and regulation. Thus, the potential role of EB1
and apoptosis in carcinogenesis requires closer attention. We also
found that HT-29 cells following EB1 knockdown had decreased
proliferation, cyclinD1, and c-myc expression but caused no change
in the HCT-116 cell lines. As it was previously proposed that EB1
may disrupt APC regulation of the WNT signaling pathway, the al-
tered phenotypes may be due to the different APC status of each
cell line [18,19]. It has been shown that together APC and EB1 reg-
ulate the mitotic spindle, chromosome alignment and microtubule
stabilization [14,34]. Dysregulation of the APC-EB1 interaction,
through APC mutation or EB1 overexpression, may therefore pro-
mote cellular proliferation, spindle defects, and aberrant chromo-
somal segregation. Genetic instability, such as chromosomal
instability (CIN), initiates cancer development, progression, and
the multiplicity of mutations in tumors [35]. The dysregulation
of the EB1-APC may therefore contribute to CIN in CRC initiation
and progression, which is consistent with our results that EB1
plays an important role in early and ﬁeld carcinogenesis.
Field carcinogenesis is the concept that the genetic/epigenetic
and environmental milieu that results in a neoplastic lesion ex-
tends throughout the affected organ [36]. Thus, alterations in the
diffuse ﬁeld provide a mutational background and predisposition
to carcinogenesis, while the initial neoplastic lesion occurred as a
result of stochastic mutations [37]. Genomic instability is a com-
mon feature of early cancer development and ﬁeld carcinogenesis
in several cancers [36,38,39]. Therefore, our ﬁndings in the diffuse
ﬁeld of the organ and pre-malignant tissue suggest that EB1 up-
regulation is one of the earliest events in colon carcinogenesis.
To further examine the effect of EB1 loss in colon cancer cell lines,
we also used the novel LEBS technology to assess the micro-archi-
tectural consequences in cells. LEBS markers are robustly sensitive
to detecting the ﬁeld effect in microscopically-normal tissue in hu-
man pancreatic and colorectal cancers [24,26,40]. Biologically,
LEBS is capable of identifying nano- and micro-architectural alter-
ations in cells, which in epithelial cells would correspond to struc-
tures such as the cytoskeleton [31]. Following EB1 knockdown, the
LEBS marker was signiﬁcantly altered in the HT-29 cells (56% effect
size change), but to a lesser degree in the HCT-116 cells (21% effect
size change), indicating that EB1 loss induced signiﬁcant, distinct
alterations in nano-architecture between cell lines. Given that LEBS
is well suited for morphological analysis of tissue architecture, this
technique would be important for the assessment of in vivo effects
of EB1 dysregulation on tissue micro-architecture.
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